Showing 1 - 4 results of 4 for search 'Michelle D. Garrett', query time: 0.03s Refine Results
  1. 1
    Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.

    Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. by Simon R Stockwell, Georgina Platt, S Elaine Barrie, Georgia Zoumpoulidou, Robert H Te Poele, G Wynne Aherne, Stuart C Wilson, Peter Sheldrake, Edward McDonald, Mathilde Venet, Christelle Soudy, Frédéric Elustondo, Laurent Rigoreau, Julian Blagg, Paul Workman, Michelle D Garrett, Sibylle Mittnacht

    Published 2012-01-01
    Get full text
    Article
  2. 2
    Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.

    Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2. by M Cris Silva-Santisteban, Isaac M Westwood, Kathy Boxall, Nathan Brown, Sam Peacock, Craig McAndrew, Elaine Barrie, Meirion Richards, Amin Mirza, Antony W Oliver, Rosemary Burke, Swen Hoelder, Keith Jones, G Wynne Aherne, Julian Blagg, Ian Collins, Michelle D Garrett, Rob L M van Montfort

    Published 2013-01-01
    Get full text
    Article
  3. 3
    Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

    Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor by Steven R. Whittaker, Clare Barlow, Mathew P. Martin, Caterina Mancusi, Steve Wagner, Annette Self, Elaine Barrie, Robert Te Poele, Swee Sharp, Nathan Brown, Stuart Wilson, Wayne Jackson, Peter M. Fischer, Paul A. Clarke, Michael I. Walton, Edward McDonald, Julian Blagg, Martin Noble, Michelle D. Garrett, Paul Workman

    Published 2018-03-01
    Get full text
    Article
  4. 4
    Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

    Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of th... by Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis

    Published 2017-01-01
    Get full text
    Article

Search Tools: